

12	STUDY IMPLEMENTATION	2
12.1	Participant Accrual and Follow-up in HPTN Studies.....	2
12.1.1	Accrual	2
12.1.2	Enrollment	3
12.1.3	Over-enrollment	3
12.1.4	Investigator-initiated Termination of Participants	4
12.1.5	Participant Unblinding.....	4
12.1.5.1	Partial or Early Unblinding - Non-Emergency Unblinding of Individual Participants for Medical Reasons	4
12.1.5.2	Full - Planned Unblinding of Participants after Study Completion	4
12.1.5.3	Emergency Unblinding of Individual Participants.....	5
12.1.5.4	Accidental Unblinding.....	5
12.2	Data Collection	5
12.2.1	Participant Research Records.....	5
12.2.1.1	Participant Research Record Contents	6
12.2.1.2	Concept of Source Data and Source Documentation.....	6
12.2.1.3	Chart Notes	7
12.2.1.4	eCRFs and Other Study Data	7
12.2.1.5	Electronic Records	7
12.2.1.6	LDMS Specimen Tracking Sheets Provided by the LC	8
12.2.1.7	Study Product Dispensing and Accountability Records	8
12.2.1.8	Document Storage and Retention	8
12.2.2	Data Collection and Management	9
12.3	Standard eCRF Elements and Forms	9
12.4	Study Team Communications.....	9
12.5	Reporting	10
12.5.1	Confidentiality of Study Data	10
12.5.2	Enrollment, Visit Completion/Retention Reports	10
12.5.3	Data Quality Control.....	10
12.5.4	Data Management Quality Reports	11
12.5.5	SMC Reports	11
12.5.6	Data and Safety Monitoring Board (DSMB) Reports	12
12.5.7	Modification of Study Recommended by DSMB.....	13
12.5.8	Reporting of Protocol Deviations	13
12.6	For-Cause Suspension of Clinical Research Sites (CRS)	14

12 STUDY IMPLEMENTATION

Once a site has received a study Activation Notice from the HPTN Leadership and Operations Center (LOC), the site may initiate study procedures. Detailed study implementation guidelines are included in the Study-Specific Procedures (SSP) manuals for each study (see Section 10.1.7).

This section includes general guidelines, applicable to all HPTN studies, on participant accrual and follow-up (Section 12.1), data collection and documentation (Sections 12.2 and 12.3), and reporting (Section 12.5).

12.1 Participant Accrual and Follow-up in HPTN Studies**12.1.1 Accrual**

Study-wide accrual targets will be specified in HPTN protocols, based on the scientific objectives and statistical considerations of each study. Site-specific targets may be described in the SSP manuals. Unless otherwise specified, study-wide accrual periods are considered to begin on the first day of participant enrollment at any participating study site; site-specific accrual periods are considered to begin on the first day of participant enrollment at that site. For many studies, the time from the first day of participant screening through the end of participant accrual will also be tracked and reported.

In addition to the total number of study participants, multi-site studies typically have an estimated number of participants to be enrolled at each participating study site indicated in the protocol, often with provisions to shift enrollment targets across sites in response to actual site performance in meeting accrual targets. Protocol teams should consider whether to specify a maximum number of enrolled participants for any site to ensure that one or more sites or populations of interest are not inappropriately over-represented in the study data. The protocol team leadership will take the lead in making this determination.

In studies for which enrollment targets are shifted across sites, the responsible Institutional Review Boards (IRBs)/Ethics Committees will be informed of increases or decreases in enrollment targets in accordance with IRB/Ethics Committee and/or single IRB requirements. At a minimum, updates are provided to IRBs/Ethics Committees and/or single IRB at least annually in the context of obtaining continuing review of ongoing studies.

In some cases, HPTN protocols include guidelines for adding participants to achieve a certain number of fully evaluable participants. In this setting, protocol teams should consider whether to specify a maximum total number of enrollees. The protocol team leadership will take the lead in making this determination.

The HPTN LOC Clinical Research Manager (CRM) discusses accrual plans with site staff during study-specific training. They will emphasize the importance of closely monitoring the accrual process at each site and managing the last several weeks of the accrual period (when inadvertent over-enrollment is most likely to occur). For example, training materials may highlight the need to inform potential study participants screened toward the end of the accrual period that even if they meet the criteria for enrollment, there is no guarantee that they will be enrolled in the study if the study quota is reached before the participant is enrolled.

For each HPTN study, the Statistical and Data Management Center (SDMC) generates routine study enrollment and retention reports from the primary study database (see also Sections 12.5.2 and 12.5.3) as specified in the study reporting plan in the Study Progress, Data and Safety Monitoring Plan (SPDSMP). Protocol teams are responsible for reviewing the SDMC enrollment and retention reports on an ongoing basis during the study accrual period and taking action as necessary to ensure that accrual and retention targets are met.

12.1.2 Enrollment

For each HPTN study, screening and enrollment procedures are described in detail in the study protocol and SSP manuals. Information pertinent to participant screening and enrollment is provided in the remainder of this section.

From both a statistical and operational perspective, it is important to define the effective point of enrollment in a research study in the study protocol and/or SSP manuals. A few examples of the definition of enrollment are as follows:

- The point in time when a participant provides informed consent for study participation (adequately completed with signature and date)
- The point in time when a participant is assigned to a study group

Written informed consent must be obtained from all HPTN study participants prior to the performance of any protocol-specified screening or enrollment procedures. See Section 8.5 for additional information on the informed consent process.

It is the responsibility of each site's Investigator of Record (IoR) and designated staff to establish study-specific participant recruitment plans or Standard Operating Procedures (SOPs) for each HPTN study and ensure that only persons who meet study eligibility criteria are enrolled in HPTN studies.

The DAIDS SCORE Manual policy on [Essential Documents](#) requires study sites to document HPTN study screening and enrollment/randomization activities on screening and enrollment/randomization logs. Screening and enrollment/randomization logs may be maintained separately or combined into one log.

For all HPTN studies, Participant Identification numbers (PTIDs) will be assigned by an electronic data capture system at screening or enrollment, as appropriate to the study. Detailed information on the assignment, structure, and format of the PTIDs to be used in each study, and instructions for assigning PTIDs to individual study participants, are provided in SSP manuals. The DAIDS SCORE Manual specifies requirements for maintaining screening and enrollment/randomization logs, in addition to PTIDs.

12.1.3 Over-enrollment

In addition to ensuring that accrual targets are met, protocol teams are also responsible for ensuring that accrual targets are not substantially exceeded. During the study accrual period, based on both the site-generated and SDMC-generated accrual reports, the protocol team leadership is responsible for proactively addressing potential over-enrollment and under-enrollment issues. Toward the end of the accrual period the protocol team leadership takes the lead in determining whether to allow eligible participants who initiate, but do not complete, the study screening process before the accrual target was met to complete the screening process and enroll in the study after the accrual target was met. In most cases, over-enrollment greater than 5% of the target study sample size or more than 50 participants — whichever is smaller — should not occur. Protocol teams should consult the HPTN Study Monitoring Committee (SMC) if higher rates of over-enrollment are to be considered.

Over-enrollment is not permitted to "make up for" participant loss-to-follow-up, unless specifically directed by the HPTN SMC, HPTN Executive Committee (EC) or the Division of AIDS (DAIDS) Data and Safety Monitoring Board (DSMB). Adjustments to the sample size initially estimated in the study protocol may be made at the recommendation of the HPTN SMC, HPTN EC and/or the study DAIDS DSMB, based on actual event rates observed among enrolled participants. If the sample size required to achieve the power specified in the study protocol is adjusted per recommendation of the SMC, EC or DSMB, the over-enrollment specifications will then apply to the final adjusted sample size.

12.1.4 Investigator-initiated Termination of Participants

HPTN study participants may withdraw their consent to participate in HPTN studies at any time, for any reason. However, to avoid biasing study results, investigator-initiated termination of HPTN study participants should occur only under extraordinary circumstances. For instance, termination may be considered if there is potential for harm to study staff or severe disruption of study operations.

In studies involving study products or interventions, IoRs will not routinely terminate study participants solely because the participants, for any reason, are non-adherent to the protocol-specified regimen for use of the study product or intervention.

In all cases, prior to terminating a participant from an HPTN study, the IoR will seek approval of the protocol team leadership; at a minimum, the Protocol Chair, DAIDS Medical Officer, HPTN CRM, and protocol statistician should consult the protocol specific-Clinical Management Committee (if applicable). Designated members of the protocol team will assess the scientific, operational, and statistical implications of the requested termination and determine whether the termination may take place.

The team's determination will be documented in writing (via email or meeting minutes) and this documentation will be filed on-site in the participant files and in the participant study termination case report form. Site staff must always record reasons for termination in participant study records.

12.1.5 Participant Unblinding

The [DAIDS SCORE Manual](#) identifies three types of unblinding: 1) Planned Unblinding (partial and full), 2) Emergency Unblinding, and 3) Accidental Unblinding.

12.1.5.1 Partial or Early Unblinding - Non-Emergency Unblinding of Individual Participants for Medical Reasons

Whether non-emergency unblinding of individual participants for medical reasons is allowed during the conduct of a clinical trial must be stated in the protocol and the procedures documented in the SSP manuals. In general, non-emergency unblinding of participants during conduct of a clinical trial is not allowed unless there are compelling medical reasons. Such scenarios will be described in the protocol and/or SSP manuals.

12.1.5.2 Full - Planned Unblinding of Participants after Study Completion

The protocol team, in conjunction with the SDMC and Laboratory Center (LC), determines the timing of participant unblinding. Except in unusual circumstances, the unblinding of participants cannot occur until all participants have completed their final data collection visit.

For Phase I/II trials, participants may be unblinded prior to complete database lock, as per the protocol team and SDMC.

For Phase IIb or III trials intended to contribute to a regulatory submission, unblinding of participants cannot occur until the study database at the SDMC is formally locked for the primary analysis.

Phase IIb or III trials that are not intended to contribute to a regulatory submission may unblind participants after all participants have completed their final data collection visit and may be before database lock.

Blinded trials that have been terminated before completion due to sponsor decision or DSMB recommendation will unblind participants as soon as practical even though the study database will not immediately be closed and locked. This decision and the timing of unblinding are the responsibility of the protocol team, in consultation with the DSMB when applicable.

The protocol team leadership will determine the method of informing participants of their blinded random assignment. In some situations, "Dear Participant" letters will be appropriate. In settings where mailing letters is not possible or appropriate (e.g., for reasons of confidentiality) it will be necessary to plan for disclosure of randomization to participants in person. If disclosure of the random assignment requires counseling of the participant or could cause distress, it should be done in person. The study site staff may consult with their Community Advisory Board (CAB) to determine the most appropriate method of unblinding participants and in developing participant letters or counseling materials. The site IoR will make a good faith effort to inform all trial participants of their individual treatment assignment.

The protocol statisticians at the SDMC will generate unblinding lists for each site per SDMC SOPs. The lists will be provided to the study site via password-protected electronic file or through a secure data transfer system (i.e., ATLAS).

12.1.5.3 Emergency Unblinding of Individual Participants

Emergency unblinding at the request of the IoR for medical or safety reasons occurs when, in the judgment of the IoR, immediate information is needed to determine appropriate care for the participant after a medical event. Per the [DAIDS SCORE Manual](#), all protocols will include information and procedures for emergency unblinding.

12.1.5.4 Accidental Unblinding

Accidental unblinding occurs when treatment assignment information is revealed to study site staff and/or participants prematurely, unintentionally, or otherwise outside of the standard process (e.g., verbal or written accidental disclosure of participant's treatment assignment, identification of the blinded study product based on its appearance, study product labelling error, and/or laboratory testing conducted outside of the trial procedures). The IoR must report any accidental unblinding that has occurred to the protocol team, DAIDS, and the IRB/Ethics Committee as soon as possible.

12.2 Data Collection

Study site staff are responsible for the collection, storage, timely submission, and quality assurance of study data collected at their site and documenting the plan for these tasks in a Data Management SOP. All study data should be collected in accordance with applicable specifications of the DAIDS SCORE Manual policy on [Source Documentation](#) and SSP manuals.

In addition, the site is responsible for maintaining all documentation critical to the conduct of the study, known as "essential documents", in accordance with the DAIDS SCORE Manual policy on [Essential Documents](#).

12.2.1 Participant Research Records

The United States (US) Code of Federal Regulations (CFR) and [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use \(ICH\) E6 guidance](#) (use the Work Products drop down menu in webpage) require study site staff to maintain adequate and accurate participant "case history records" containing all information pertinent to the study for each HPTN study participant.

12.2.1.1 Participant Research Record Contents

Participant research records should contain all of the following elements:

- Basic participant identifiers such as PTID or initials
- Documentation that the participant provided written informed consent to participate in the study prior to the conduct of any study procedures
- Documentation that the participant met the study's eligibility criteria
- A record of the participant's randomization assignment (if applicable)
- A record of the participant's exposure to study products (if applicable)
- A record of all contacts, and attempted contacts, with the participant including all clinic visits, off-site visits (e.g., at home or work), and all verbal and written contacts
- A record of all procedures performed by study staff during the study
- Complete source documents
- All electronically captured case report forms (eCRFs) and other study data collected from the onset of screening through end of participation
- Study-related information on the participant's condition before, during, and at the conclusion of study participation, including:
 - subjective data obtained directly from the participant (e.g., interview responses)
 - objective data ascertained by study staff (e.g., exam and laboratory findings)
 - objective data obtained from non-study sources (e.g., medical records, including electronic medical records (EMR) or electronic health records (EHR))

In addition to the above, the DAIDS SCORE Manual policy on [Source Documentation](#) requires that all protocol deviations involving participants be documented in participants' study records, along with reasons for the deviation and attempts to prevent or correct the deviations, if applicable. See Section 12.5.8 regarding requirements for reporting protocol deviations.

12.2.1.2 Concept of Source Data and Source Documentation

The ICH/GCP guidance defines source data and source documentation as follows:

- The term "source data" refers to all information in original records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents (original records or certified copies).
- The term "source documents" refers to original documents, data and records (e.g., hospital records; clinical and office charts; laboratory notes; memoranda; subjects' diaries or evaluation checklists; pharmacy dispensing records; recorded data from automated instruments; copies of transcriptions certified after verification as being accurate and complete; microfiche; photographic negatives; microfilm or magnetic media; x-rays; subject files; and records kept at the pharmacy, the laboratories, and medico-technical departments involved in the trial).

Source documents are commonly referred to as the documents — paper-based or electronic — upon which source data are first recorded.

Source documentation includes original documents and certified copies that include documentation pertaining to a participant while on study. HPTN study sites must adhere to the standards of source documentation specified in the DAIDS SCORE Manual policy on [Source Documentation](#). This policy contains both requirements and recommendations. Study sites must comply with all requirements and are advised, but not required, to comply with all recommendations.

As a condition for study activation, each site must establish an SOP for source documentation that specifies the use of these documents as source documents.

Supplemental information on the use of chart notes, visit checklists, eCRFs, and electronic data capture (EDC) as source documents is provided below. Also provided below is information related to study product dispensing and accountability records, document organization, and record retention requirements.

12.2.1.3 Chart Notes

Chart notes must be used to document the following:

- Procedures performed that are not recorded on other source documents
- Pertinent data about the participant that are not recorded on other source documents
- Protocol deviations that are not otherwise captured on other source documents

All chart notes or other tools created for the study used as source documentation must document the PTID of the study participant to whom it pertains, the identity of the study staff member who entered information, and the date of the entry. Study sites are strongly encouraged to adopt a common format — such as the Subjective-Objective-Assessment-Plan (SOAP) format for all chart notes, to help ensure adequacy and consistency of note content and maximize adherence to GCP standards: [Example SOAP Chart Note](#). Alternative standardized formats are acceptable and may be adopted by study sites; however, sites are encouraged to also adhere to the DAIDS SCORE Manual policy on [Source Documentation](#).

12.2.1.4 eCRFs and Other Study Data

The SOP for source documentation requires that a site must document the source for every data element collected on the eCRFs. Study staff must follow the specifications of this SOP consistently for all study participants throughout the study. In general, it is expected that a paper or electronic source record will be used for every data element entered into an eCRF other than participant self-reported. Any data element entered directly into the eCRF must be documented in the study protocol. In the event that study staff are not able to record specified source data directly onto forms designated as source documents (e.g. participant self-report), or directly enter the data into the study database, the following procedures should be undertaken:

- Recording the data onto an alternate source document
- Entering the alternate source document into the participant's study chart
- Transcribing the data from the alternate source document onto the appropriate eCRF
- Recording a chart note stating the reason why an alternate source document was used

12.2.1.5 Electronic Records

Electronic records are any combination of text, graphics, data, pictorial, or other information in digital form that is created, modified, maintained, archived, retrieved, or distributed by a validated computer system (21 CFR 11.3). When data are entered directly into a computer, the electronic data in the computer becomes the source document. A paper record (printout/hard copy/"print screen") of the electronic data is considered to be a copy. Requirements for documentation, record keeping, and record retention apply to electronic records the same as they do for paper systems.

Examples of electronic records include but are not limited to:

1. Participant data, reports, and/or results
2. Email communications pertaining to a participant or protocol management
3. IRB/Ethics Committee and/or single IRB correspondence pertaining to a participant or the study

Each electronic record needs to be associated with an originator type, otherwise known as an authorized data originator. An authorized data originator could be a person, a computer system, a device, or an instrument that is authorized to enter, change, or transmit data into the electronic record. Sites must develop and maintain a list of all authorized data originators. This list must be made available for study-related monitoring, audits, IRB/Ethics Committee and/or single IRB review, and regulatory inspection by authorized individuals at each clinical research site. In the case of electronic participant-reported outcome (ePRO) measures, list the participant (e.g., unique participant identifier) as the originator.

Examples of data originators include, but are not limited to:

1. Clinical investigator(s) and delegated clinical study staff
2. Participants or their legally authorized representatives
3. Consulting services (e.g., a radiologist reporting on a computed tomography (CT) scan)
4. Medical devices (e.g., electrocardiograph (ECG) machine and other medical instruments such as a blood pressure machine)
5. Electronic health records (EHRs)
6. Automated laboratory reporting systems (e.g., from central laboratories)
7. Other technology

12.2.1.6 LDMS Specimen Tracking Sheets Provided by the LC

The Laboratory Data Management System (LDMS) Specimen Tracking Sheet is designed to accompany specimens from the clinic to the site's laboratory and facilitate entry of specimens into LDMS. A study-specific LDMS Specimen Tracking Sheet may be provided by the LC, but sites may elect to use their own laboratory requisition forms instead.

12.2.1.7 Study Product Dispensing and Accountability Records

As indicated in Section 10.2, the receipt, dispensing, and final disposition of all study product supplies used in HPTN studies must be documented by designated study site staff in accordance with the [Pharmacy Guidelines and Instructions for DAIDS Clinical Trials Networks](#) or study-specific HPTN Pharmacy Study Product Management Procedures Manual as applicable (see Section 23), as well as any supplemental instructions provided in the study protocol and/or Pharmacy SSP Manual.

12.2.1.8 Document Storage and Retention

All participant study records must be stored securely at the study site in accordance with the specifications of the study protocol. See Section 8.9 for additional considerations related to participant confidentiality. Information on long-term storage and retention of study documents can be found in Section 18.2.

12.2.2 Data Collection and Management

The SDMC uses Medidata Rave or other EDC systems for eCRF data entry and management for HPTN studies. The SDMC may use other systems for collection of study data, such as Audio Computer Assisted Self-Interview (ACASI) or electronic Clinical Outcomes Assessment (eCOA) software. Information and procedures for the specific data collection tools used for each study are included in the SSP.

12.3 Standard eCRF Elements and Forms

All HPTN eCRFs have been designed using standards and conventions developed by the SDMC. Certain eCRFs have been standardized within the HPTN to ensure that all required data is collected to create as much consistency as possible between protocols. These elements also align to the extent possible to the Clinical Data Interchange Standards Consortium (CDISC) standards as required by the National Institute of Allergy and Infectious Disease (NIAID). Instructions for study staff on correct completion of each of these CRF elements are included in Case Report Form Completion Guidelines (CCGs) with additional information provided in SSP manuals and online in the Medidata system.

12.4 Study Team Communications

After initial release of a study protocol and SSP manuals, several types of study-related communications may be issued to report on study progress or provide further clarification of protocol-specified procedures and study documentation requirements. Such communications may include, but are not limited to, the following:

- *Conference call and meeting summaries*: Protocol teams, and in some cases, other designated study working groups, take part in routine meetings and conference calls throughout the period of study implementation. Summaries of these meetings and conference calls, which often document key protocol-related and study implementation decisions and action items, are prepared and distributed as described in Section 6.2.
- *Protocol Clarification Memos, Letters of Amendment, and Full Protocol Amendments with an attendant summary of revisions*: These documents are developed and issued as described in Section 9.3. Development of these documents is coordinated by the HPTN CRM, and final versions are distributed to all protocol team members and study sites. Final versions also are posted on the HPTN website and the study share portal.
- *SSP manual updates*: These updates are developed and issued as described in Section 10.1.7. Like the initial version of the SSP manuals, development of the updates is coordinated by the HPTN CRM, and final versions are posted on the study share portal.
- *Data Communiqués*: These documents are developed and issued by the SDMC CDM to clarify issues related to study data collection. Final versions are distributed to all study sites for posting on the study share portal. They are considered an official part of the SSP manual.
- *Laboratory Communiqués and Operational Memos*: These documents are developed and issued by the LC HPTN QA/QC representative to clarify issues related to laboratory procedure. Final versions are distributed to all study sites for filing in the Laboratory Manual and are posted on the study share portal. They are considered an official part of the manual.
- *Reports*: Data reports on study progress, protocol adherence, data quality, etc., are developed and issued by the SDMC in accordance with the study reporting plan (see Section 12.5). They are also posted on the SDMC web portal.

- *Study implementation questions:* Site questions about study implementation should be directed to the LC, HPTN CRM and the SDMC CDM. They will determine between them who is the most appropriate person to respond. They will also forward the query to another party for a response if deemed appropriate. In cases where the LC representative, HPTN CRM and SDMC CDM determine that the question and answer may be relevant or informative to staff from other study sites, they will forward the information to relevant site staff. They also may raise the issue for discussion during study-related conference calls and/or issue a more formal communication (e.g., SSP manual update, Clarification Memo, or Data Communiqué) to properly address the issue.

All of the above-listed communications are issued with specific instructions for filing and further distribution as appropriate. Recipients are responsible for filing copies of documents as instructed and for communicating relevant information contained in the documents to all applicable study staff members, collaborators, etc.

12.5 Reporting

The HPTN has developed standardized reporting for tracking study progress and site performance.

A study reporting plan is prepared by the SDMC statisticians prior to the start of the study. The reporting plan lists the types and frequencies of reports to be produced for a given study. The approved reporting plan is included in the SPDSMP. Reports that are generally included are:

- Enrollment and retention
- Data management quality
- SMC
- DSMB

12.5.1 Confidentiality of Study Data

The disclosure of study endpoints or any follow-up data that might be predictive of/correlated to study endpoints during an ongoing study should be limited to designated committees (e.g., closed SMC, DSMB) to avoid bias in study conduct and/or interpretation of data.

12.5.2 Enrollment, Visit Completion/Retention Reports

During the protocol accrual period, the SDMC routinely generates protocol-specific enrollment reports showing expected and actual participant enrollments. The SDMC also generates protocol-specific reports on participant visit completion, as an estimate of retention, for each scheduled study visit. Details of these reports are included in the reporting plan included in the SPDSMP and are available on the SDMC web portal.

12.5.3 Data Quality Control

For EDC, much of the data QC is performed by real-time field-level and cross-form data checks programmed into the system by the SDMC. In addition to these real-time checks, data queries regarding missing pages or items that require more clarification by site staff will appear in a task summary or other reports. In general, site staff should respond to any data queries within 7 days, or 48 hours for queries regarding safety data and adverse events.

12.5.4 Data Management Quality Reports

The SDMC routinely generates reports on site-specific and protocol-specific data management performance. These reports include:

- Number and percentage of CRF pages entered within 7 days of study visit
- Number and percentage of Adverse Event CRFs entered within 3 days of site awareness
- Total number of items queried by the SDMC and query rate (the number of queried items per 100 CRF pages)
- Number and percentage of queries responded to within 7 days

12.5.5 SMC Reports

The HPTN SMC reviews studies as deemed necessary (see Section 4.3.2 for reporting frequency). The HPTN CRM is responsible for identifying the date of an HPTN SMC review and for arranging HPTN SMC conference calls and documenting the SMC review. The SDMC prepares reports for these reviews that include:

- Trial design
- Accrual
- Demographics and other baseline characteristics
- Summaries of reportable adverse events or social impact reporting
- Protocol and intervention adherence
- Participant study visit completion / retention
- Laboratory performance, specimen storage and quality assurance (QA) testing (with input from the LC)
- Data quality, completeness, and timeliness
- Reportable protocol deviations
- Review of aggregate safety data, for studies with a biomedical intervention without DSMB oversight. The HPTN SMC composition for these studies should include clinicians experienced in the review of safety data, who are not affiliated with the protocol team or HPTN (if there are Independent Safety Reviewers assigned to the study, they should fill this role). The HPTN SMC will review safety data only during a closed session with no study team present except for the protocol statistician to respond to HPTN SMC questions.
- Endpoint summary; Review of aggregate primary endpoints rates in efficacy studies. The HPTN SMC will review endpoint data only during a closed session, for the purpose of ensuring the study is projected to have adequate power. The DSMB will be informed of the HPTN SMC review, and minutes of these deliberations may be shared with the DSMB.

Additional information about study conduct, site-specific issues, and materials other than study data collected by the SDMC may be included as an addendum to the SDMC report. Such addenda are prepared only at the request of the SMC or SDMC and are typically prepared by the LOC CRM and/or other protocol team members.

After the HPTN SMC review, the HPTN LOC distributes a summary to the protocol team, and at that time the HPTN SMC report may be shared with members of the protocol team.

12.5.6 Data and Safety Monitoring Board (DSMB) Reports

A NIAID DAIDS Multinational DSMB periodically reviews data reports from all Phase IIb/III HPTN trials and other selected studies. The primary responsibilities of the DSMB are to:

- Safeguard the interests of study participants
- Preserve the integrity and credibility of the trials in order that future individuals will benefit from optimal prevention therapy
- Ensure that definitive and reliable results will be available in a timely way to the medical community

To do this, the multidisciplinary panel of DSMB members conduct comprehensive reviews to evaluate the:

- Study design and statistical analysis plan
- Accumulated efficacy data, typically according to formal interim analysis plan
- Integrity of the trial with regard to accrual, eligibility, compliance, and retention

Typically, a report is prepared by the SDMC for review by the DSMB. It is composed of an open report in which data are presented aggregated across treatment arms and a closed report containing data presented by treatment arm, masked or unmasked. Topics covered in the report include:

Open report (data not reported by arm):

- Trial design and history
- Accrual
- Baseline characteristics
- Adherence
- Participant status and retention
- Serious and non-serious adverse events
- Data quality and timeliness
- Reportable protocol deviations
- HPTN SMC review summary

Closed report (data reported by arm — masked or unmasked):

- Accrual
- Baseline characteristics
- Retention
- Adherence
- Participant status and termination
- Efficacy endpoints
- Safety endpoints
- Other secondary outcomes

After the DSMB review, a summary is distributed by the HPTN LOC to investigators for submission to the site IRBs/Ethics Committees, unless otherwise directed by DAIDS. For any study that will be conducted at more than one US site, DSMB summaries are submitted by the HPTN LOC for single IRB review on behalf of all US sites.

12.5.7 Modification of Study Recommended by DSMB

In the event of a recommendation, the information from the DSMB is shared only with NIAID. NIAID communicates the recommendation to HPTN leadership. This leadership team includes:

- Network Principal Investigator(s)(PI)
- LC PI(s)
- HPTN LOC Director
- SDMC PI(s)
- Others as deemed necessary

Prior to NIAID's release of a press release or public statement, it is imperative that the DSMB findings remain confidential. In an effort to ensure study confidentiality, all study team members must sign a confidentiality agreement.

Recognizing that in some cases DSMB findings may require immediate action, communication of DSMB results with network constituents and study participants will be coordinated with the Protocol Chairs, HPTN leadership, and NIAID in a timely fashion. Advance communication planning and development of possible DSMB outcomes will expedite this process.

12.5.8 Reporting of Protocol Deviations

The [Cross-Network Protocol Deviation Reporting Guide](#) (reporting guide) establishes standard definitions and classifications for protocol deviations (PDs) and is to be utilized for HPTN studies. In addition, the reporting guide describes the process for reporting protocol deviations via the PD eCRF.

Reportable PDs are those that may significantly impact the completeness, accuracy, and/or reliability of key study data or that may significantly affect a participant's rights, safety, or well-being and must be reported via the PD eCRF within 5-reporting days of awareness (see reporting guide). Not reportable PDs are those that do not meet the definition of a reportable PD.

All sites must complete a Corrective and Preventive Action (CAPA) form for any reportable PD. Sites may use their own or DAIDS CAPA form. The CAPA form in addition to the corrective plan, must minimally include the protocol number, site name, site number, PTID, and date(s), as per the PD eCRF, for the respective protocol deviation.

Note that all protocol deviations must also be recorded in the participant's research record. See the [Source Documentation Requirements](#) section of the DAIDS SCORE manual for further guidance. Full documentation of all protocol deviations including reportable deviations for each study should be maintained at the site and reported as needed to the local IRB/Ethics Committee and/or single IRB. A brief description of the deviation is sent via email to the Protocol Chairs, IoR, Site Study Coordinator, Site QA/QC Coordinator(s), HPTN CRM, SDMC PM, LC representative, DAIDS Prevention Science Program (PSP)/[Office of Clinical Site Oversight](#) (OCSO) representative for the site, the DAIDS Medical Officer for the study and, if the deviation involves a study product, the DAIDS PAB Pharmacist or HPTN Pharmacist as applicable (see Section 23). Per the requirements of 45 CFR 46.108(a)(4) and 21 CFR 56.108b, site investigators are responsible for promptly reporting to their IRB/Ethics Committee and/or single IRB all unanticipated problems involving risks to human subjects or others and serious or continuing noncompliance with applicable regulations or the requirements or determinations of their IRBs/Ethics Committees and/or single IRB.

DAIDS will review all deviations periodically. Required protocol team review may be included in the protocol and other implementation materials; if not specified in the protocol or other implementation materials, deviations may also be reviewed periodically by the protocol team. Based on this review, queries may be sent to re-classify the deviation or add greater detail to the deviation description. In addition, DAIDS, Network groups, and/or protocol teams may request sites send the full details of the corrective/preventative action plan.

The HPTN has established a process for staff at HPTN study sites, the HPTN LOC, LC, and SDMC to document the occurrence of protocol deviations and to report them to the protocol team, particularly those that might otherwise not be evident in the study data or reported otherwise. After consultation with the HPTN LOC, SDMC, and LC representatives, all deviations that meet the criteria in the reporting guide will be recorded on the PD eCRF.

The Clinical Site Monitor identifies protocol non-adherence events and violations in their monitoring reports, and some of these may also be reportable protocol deviations; however, there is not a one-to-one correlation between events reported by the Clinical Site Monitor and those to be reported through the HPTN protocol deviation reporting system. The Clinical Site Monitor may report protocol non-adherence events and violations that encompass every infraction of the protocol. For example, if a blood specimen is drawn for alanine transaminase (ALT), but is not processed by the laboratory, it is a non-adherence event according to the Clinical Site Monitor. This would not be a reportable protocol deviation. If, however, an ALT is to be drawn at each patient visit and is not being done at all, this would be a reportable protocol deviation.

12.6 For-Cause Suspension of Clinical Research Sites (CRS)

If concerns are identified that may result in a for-cause suspension of study activities at a CRS, the person identifying the concerns must notify the DAIDS OCSO Program Officer (PO) and Network Liaison(s) as soon as possible.

The OCSO PO will initiate the suspension process and collaborate with stakeholders to review concerns and determine if a suspension is needed. If it is determined that a suspension is needed, the OCSO PO sends the initial suspension notification to the CRS.

- If an urgent need arises, the HPTN LOC may send the initial suspension notification to the CRS, then follow-up with OCSO PO and OCSO Network Liaison(s) to continue the process. An urgent example includes imminent participant safety concerns that cannot await an immediate discussion with OCSO.

After the initial suspension notification is sent, the OCSO PO collaborates with the HPTN LOC and relevant stakeholders to identify requirements for lifting the suspension and communicates them to the CRS.

The OCSO PO coordinates with the HPTN LOC and relevant stakeholders to make sure requirements for lifting the suspension are met and that any CAPAs have been addressed. Once all requirements and CAPAs have been addressed to the satisfaction of stakeholders, OCSO communicates the decision to lift the suspension.

All communications throughout this process must include the CRS Leader, CRS Coordinator, Clinical Trials Unit PI (if applicable), DAIDS MO, Protocol Chairs, HPTN LOC, LC, and SDMC.